Functional Fluidics offers a suite of assays to clinical providers, pharmaceutical, academic, and biotech partners to help support new drug development and overall patient care.
Functional Fluidics is striving to be the gold standard in red blood cell (RBC) health, beginning with Sickle Cell Disease. We provide monitoring services for clinical studies using our assays to quantify the effects of a drug on blood function over time. We also partner with Clinicians to develop companion diagnostics to help enable them to pair the right treatment with the right patient, at the right time.
Services for Clinical Providers, Academic, Pharma & BioTech Partners
Our proprietary biomarker support drug validation and patient monitoring:
- Clinical Providers on the front lines caring for patients who need clinical tools to help monitor care.
- Pharmaceutical & Biotech companies developing therapies that affect the health of red blood cells
- Academics studying subjects and measurement of blood function through baseline and crisis events.
Functional Fluidics offers the following services
Send Out Testing Services for Clinicians
The clinical pain and fatigue characteristic of sickle cell disease is difficult to objectively quantify. Clinicians cannot depend on their physical exam, imaging studies, or laboratory data to validate claims of pain by their patients. This challenge often creates physician and patient dissatisfaction and makes it difficult to assess individual patient response to modifying therapy.
Functional Fluidics is a certified CLIA lab with biomarkers that may help objectively assess patient-reported outcomes (PROs) and response to disease modifying therapy.LEARN MORE
Contract Research Services for Pharma and Biotech Companies
Functional Fluidics is well-positioned to address the needs of clients with large-scale validation studies and provide insights into the individual patient-level response critical for development of personalized medical applications. Our CLIA-certified lab is available for both high-throughput cell function testing, and to assaying unique patient samples, to answer questions related to drug safety of mechanisms of action.
Functional Fluidics provides testing solutions to support our pharmaceutical and academic research partners across the continuum of drug development, with a specialized focus on red blood cell modifying therapies.LEARN MORE
Why Choose Functional Fluidics?
Proprietary Lab Tests
CLIA Certified Lab
Complex Tests Experience
Thought Leader Access
Strong Industry Relationships
Functional Fluidics Assays
Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)
Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.
Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.
The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.LEARN MORE
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers
Functional Fluidics Biomarker Assay Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine
- Feasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.
- ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.
Publications & Abstracts
Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay
The objective of this study was to identify hematologic lab values that contribute to cellular adhesion in our clinical adhesion bioassay.
Evaluation of Coagulation and Inflammatory Markers in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO)
The aims of this study were to evaluate if novel laboratory tests could better predict patients at risk for bleeding and/or thrombosis compared to routine laboratory tests
Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease
Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner
Impact of environment on Red Blood Cell ability to withstand mechanical stress
An approach to measuring RBC haemolysis and profiling RBC mechanical fragility
Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay
A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease